Sep 16th 2013 - Edison Investment Research today published a report on Nanobiotix entitled "Progress Continues; Product Reach Broadens". In summary, the report says:
NBTXR3 clinical development remains on track, with all trials progressing as planned. A €2.8m grant to develop NBTXR3 in the additional indication of liver cancer, and a collaboration with the US NCI for follow-on product NBTX-IV broaden the medical and geographical reach of Nanobiotix’s products. Cash of €8.1m (excluding the €2.8m) should still be sufficient to fund operations to mid-2014. Our €113m valuation is unchanged.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »